
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a commercial-stage biopharmaceutical company with a promising drug candidate VTAMA and several other drugs in different stages of development. The positive Phase 2 data for brepocitinib in multiple indications, strong hemodynamic profile for mosliciguat, and the validation of the anti-FcRn mechanism by multiple developers make Roivant Sciences a promising investment opportunity. However, there are risks to consider, such as regulatory and clinical uncertainties, competition in the market, and potential technical hurdles.
Bears say
Roivant Sciences is in its commercial stage, but its management has set expectations for a measured initial ramp for its plaque psoriasis treatment, VTAMA. Additionally, success in this indication has been the primary driver of the company's performance but upcoming data readouts and the potential expansion into other indications could also contribute to its success. However, investors should expect a slow and steady launch for VTAMA, and the company's other drug candidates in development may face challenges in uptake due to barriers like safety concerns and lack of physician familiarity.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares